Could a new molecule tame a rare liver disease? early safety trial begins
NCT ID NCT03099603
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This early-stage trial tests whether a single dose of HTD1801, an experimental drug for primary sclerosing cholangitis, is safe and tolerable in healthy adults. Researchers will monitor participants for side effects and measure how the drug moves through the body. The goal is to gather initial safety data to support further development of this potential treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HTD1801, an experimental small-molecule drug being developed for primary sclerosing cholangitis
- What this could lead to
- If safe and well-tolerated, HTD1801 could advance to larger studies and eventually offer a new treatment option for primary sclerosing cholangitis, a rare liver disease.
- What could go wrong
- This is an early, first-in-human study with only 32 healthy participants, so it cannot prove effectiveness. The drug may cause side effects or fail in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network Limited
Melbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outperform standard care for a rare liver disease in teens?
- Blood test may tame the tightrope walk of transplant drugs
- Artificial intelligence may help decide who gets a liver first
- AI may outsmart current system for liver transplant priority
- Could a common drug stop a rare liver disease from returning after transplant?
- New antibody aims to tame rare liver disease